NEWS
Our Latest News
ARCHIMED Successfully Completes Take-private of Esperion Therapeutics
Esperion Therapeutics is a commercial-stage biopharmaceutical company bringing innovative cardiometabolic and rare/orphan disease therapies to market for patients with unmet medical needs.
ARCHIMED buys Cellese, a pioneering developer of growth factors and exosome-based skincare products
September
4,
2024
ARCHIMED acquires Irrimax, market leader in anti-microbial wound irrigation solutions
August
28,
2024
ARCHIMED concludes successfully its £203 million take-private bid for drug development software leader Instem
November
27,
2023
ARCHIMED creates a leading specialized dermatological-focused CRO via the simultaneous purchase & merger of Symbio and Proinnovera
November
17,
2023
ARCHIMED top-ranked buyout fund MED I earns 4.5x on the sale of Vita
October
27,
2023
368